ADA 2020: Bexagliflozin Improves Glucose Control, Blood Pressure, and Weight in High-Risk Type 2 Diabetes Patients
The investigational agent also appeared to be as well-tolerated as other SGLT2 inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.